Efficacy of Different Therapies for Immunosuppression after Liver Transplantation: A Meta-analysis
- VernacularTitle:不同免疫抑制方案治疗肝移植患者疗效Meta分析
- Author:
Pingrong XU
;
Jing LU
;
Yao TANG
;
Xiaoxi WEI
- Publication Type:Journal Article
- Keywords:
FK506;
CsA;
Randomized controlled trials;
Meta-analysis
- From:
China Pharmacy
1991;0(06):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To evaluate the safety and efficacy of FK506-based dual therapy and CsA-based triple therapy for immunosuppression after liver transplantation. METHODS: The literature about the randomized controlled trials (RCT) on FK506 and CsA for immunosuppression after liver transplantation was retrieved for analysis using RevMan 5.0 software. RESULTS: A total of 7 RCTs were included; 3 were considered as high quality of RCT, 4 as moderate quality. The results of Meta-analysis of FK506-based dual therapy indicated the patients’ survival rate (RR=1.06, 95%CI=0.77～1.45,P=0.72), grafts’ survival rate (RR=0.99, 95%CI=0.76～1.29,P=0.92), infection rate(RR=0.98, 95%CI=0.60～1.58,P=0.93)and incidence of neurotoxicity (RR=0.59, 95%CI=0.32～1.07,P=0.08)was not significantly different. The incidence of acute rejection in CsA group was lower than in FK506 group (RR=1.57, 95%CI=1.23～2.01,P=0.000 3). CONCLUSION: The curative efficacy of FK506 group is not different from that of CsA group in respect of rate of patient/graft, infection but increase the incidence of acute rejection. Because CsA can increase incidence of neurotoxicity, it is suggestion to treat patients of nervous systerm disease with FK506.
